Caliway advances CBL-514 into phase 3. Two trials test Caliway Biopharmaceuticals C stock

Caliway Biopharmaceuticals C (ISIN TW0006919004) is advancing CBL-514 into phase 3 after phase 2 data showed a 69.60 percent response for subcutaneous fat reduction. Pharmaphorum reported the development on October 2, 2026, while Caliway's release described recruitment for the first of two placebo-controlled phase 3 trials.

Phase 3 follows a 69.60 percent response

The phase 2 result came from participants who received CBL-514 for eight weeks. According to Caliway Biopharmaceuticals on October 2, 2026, 69.60 percent of treated participants reduced subcutaneous fat by at least 150 milliliters, compared with 0 percent for placebo.

What does 12.01 percent mean?

MRI data from the phase 2 program showed that visceral fat volume fell 12.01 percent four weeks after treatment, while the placebo group recorded a 5.68 percent increase. The company said the research still needs to establish whether CBL-514 can reduce weight regain after GLP-1 treatment, keeping the result in an early clinical context.

Three dated markers for investors

On August 4, 2026, Caliway reported second-quarter revenue of TWD 3.57 million and a loss of TWD 222.52 million, according to Investing.com. On October 2, 2026, the company presented the 69.60 percent phase 2 response; on October 27, 2026, its Taiwan-listed stock was last quoted at TWD 67.50.

November 11 is the next date

Investing.com lists November 11, 2026, as Caliway's next earnings date. That report will give investors a new operating update while the phase 3 program moves forward.

Taiwan listing closes the picture

Caliway Biopharmaceuticals stock was last at TWD 67.50 on the Taiwan Stock Exchange on October 27, 2026 at 1:30 p.m. CST. The finance snapshot also placed market capitalization at TWD 105.1 billion and the 52-week range at TWD 66.50 to TWD 188.00.

Market context: Market report TAIEX.

More news and analyses on Caliway Biopharmaceuticals C stock